We serve Chemical Name:2-Amino-3-nitrobenzamide CAS:313279-12-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2-Amino-3-nitrobenzamide
CAS.NO:313279-12-8
Synonyms:2-amino-3-nitro-benzamide;2-Amino-3-nitrobenzamide;2-Amino-3-nitro-benzoesaeure-amid;Benzamide,2-amino-3-nitro;BEN059;2-amino-3-nitro-benzoic acid amide;Benzamide, 2-amino-3-nitro-;3-Nitro-2-amino-benzamid
Molecular Formula:C7H7N3O3
Molecular Weight:181.149
HS Code:2924299090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:319.2±22.0 °C at 760 mmHg
Density:1.5±0.1 g/cm3
Index of Refraction:1.676
PSA:114.93000
Exact Mass:181.048737
LogP:1.55
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 2-amino-3-nitro-benzamide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-Nitro-2-amino-benzamid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-amino-3-nitro-benzamide Use and application,2-Amino-3-nitro-benzoesaeure-amid technical grade,usp/ep/jp grade.
Related News: Resonant exploits its proprietary IMPaCT tumor microenvironment models and data platform to discover novel, unappreciated targets and functionally active anti-tumor antibodies for difficult to treat tumors. 2-Amino-3-nitrobenzamide manufacturer The continuous acceleration of the industrial transfer process has provided a huge market space for the fine chemical intermediate industry. 2-Amino-3-nitrobenzamide supplier Any US citizen who has been in China’s Hubei province — epicenter of the outbreak — in the last 14 days will be allowed back into the country. 2-Amino-3-nitrobenzamide vendor Resonant exploits its proprietary IMPaCT tumor microenvironment models and data platform to discover novel, unappreciated targets and functionally active anti-tumor antibodies for difficult to treat tumors. 2-Amino-3-nitrobenzamide factory ��CAR T-cell therapy continues to deliver remarkable outcomes for patients with hematologic malignancies, and next-generation approaches are needed to enable broad and timely patient access and reduce the cost and complexity of therapy,�� said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics.
